Drug Type Bispecific antibody |
Synonyms AZD 1163, AZD1163 |
Target |
Action inhibitors |
Mechanism PAD2 inhibitors(peptidyl arginine deiminase 2 inhibitors), PAD4 inhibitors(peptidyl arginine deiminase 4 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Rheumatoid Arthritis | Phase 2 | United States | 15 Dec 2025 | |
| Rheumatoid Arthritis | Phase 2 | Japan | 15 Dec 2025 | |
| Rheumatoid Arthritis | Phase 2 | Argentina | 15 Dec 2025 | |
| Rheumatoid Arthritis | Phase 2 | Brazil | 15 Dec 2025 | |
| Rheumatoid Arthritis | Phase 2 | Canada | 15 Dec 2025 | |
| Rheumatoid Arthritis | Phase 2 | Chile | 15 Dec 2025 | |
| Rheumatoid Arthritis | Phase 2 | Germany | 15 Dec 2025 | |
| Rheumatoid Arthritis | Phase 2 | Mexico | 15 Dec 2025 | |
| Rheumatoid Arthritis | Phase 2 | Ukraine | 15 Dec 2025 |
Phase 1 | 83 | fauhnkxwgf(kkfenlzfkk) = ydbmljbcbc yvlbwgtngr (xxdoeqcdws ) View more | Positive | 24 Oct 2025 |






